Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 19/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413480 | 0.91 | MAP2K2 (0.78) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL189491 | 0.91 | MAP2K2 (0.78) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL4345119 | 0.90 | MAP2K1 (0.77) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL20971438 | 0.88 | MAP2K1 (0.69) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL30220857 | 0.88 | MAP2K1 (0.82) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL188585 | 0.88 | MAP2K1 (0.82) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL29413378 | 0.87 | MAP2K1 (0.70) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL189188 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL29413551 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL3110563 | 0.87 | MAP2K1 (0.73) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | MAP2K1 62/4885MAP2K2 66/4885CHRM2 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.